PriceTracker GLP-1
Loading the index…

Try

Find the cheapest for me
Loading the index…

Try

GLP-1 TV · Clinician

Are You Taking the Wrong Kidney Drug? SGLT2 vs GLP-1 | AMA Live

Clinician32:58May 2026

Today’s cheapest GLP-1$39/mo at Wellmedr, sale price.Compare all GLP-1 prices Price read 22 Nov 2026 from the seller’s own page, ranked by price alone. That price is a compounded drug, and compounded drugs are not FDA-approved. Not from the video’s creator.

Our summary

In this members-only live Q&A, the channel, a kidney doctor, works through the five questions he says viewers ask most, then answers a few chat questions. He starts with SGLT2 inhibitors and GLP-1s in chronic kidney disease (CKD) without diabetes. He says the EMPA-KIDNEY trial of 6,609 people, 54% of whom did not have diabetes, found empagliflozin lowered kidney progression and cardiovascular death with a hazard ratio of 0.72, and that KDIGO 2024 recommends SGLT2 inhibitors regardless of diabetes status at certain kidney function and urine protein levels. For GLP-1s, he says the FLOW trial of semaglutide cut a major kidney endpoint by 24% over a median 3.4 years, but it enrolled only people with type 2 diabetes and CKD. He links this to the January 2025 FDA approval of Ozempic for kidney protection. He says the evidence for non-diabetic CKD is not there yet, though he expects positive data later.

Published by Sean Hashmi, MD on YouTube

As published by the channel. Not medical advice, and not an endorsement.

What else the video covers

He then covers creatine, foamy urine and protein targets. On creatine, he says it is considered safe in healthy people and raises serum creatinine without harming the kidneys, but that there is not enough data for stage 3 CKD and beyond, so people should tell their kidney doctor. On foam, he says it is not a diagnosis and the urine albumin creatinine ratio is the test to trust. On protein, he says KDIGO 2024 suggests 0.8 g per kilogram for stable stage 3 to 5 CKD, with a ceiling of 1.3 g per kilogram, higher targets for frail or underweight people, and a preference for plant protein.

He next lists causes of CKD fatigue: anemia and iron deficiency, sleep apnea, metabolic acidosis, fluid or blood pressure problems, and depression. In the chat, he says no continuous creatinine monitor exists. He also tells a viewer with type 2 diabetes that stable numbers matter most, and that a GLP-1 could be considered for weight loss if lifestyle changes fall short.

Our summary of what is said, in our words. Doses, results and prices are the speaker’s, not advice.

Takeaways

The main points, in the order they come up. Tap a time to play from there.

  1. 0:44 The speaker says SGLT2 inhibitors are supported in CKD with or without diabetes, while GLP-1 kidney evidence so far comes only from people with type 2 diabetes.
  2. 5:23 He says creatine is considered safe in healthy people, but data are lacking for CKD stage 3 and beyond, so a kidney doctor should be involved.
  3. 9:27 He explains that foamy urine alone is not diagnostic and that a urine albumin creatinine ratio, repeated if needed, is the reliable check.
  4. 14:09 He reports that KDIGO 2024 suggests 0.8 g of protein per kilogram in stage 3 to 5 CKD, with a 1.3 g per kilogram upper limit and higher targets for frail people.
  5. 21:27 He lists treatable causes of CKD fatigue to raise with a doctor: anemia, sleep apnea, acidosis, fluid or blood pressure issues and depression.
  6. 30:16 In a chat answer, he says stable kidney numbers are the main goal and a GLP-1 can be considered for weight loss if lifestyle changes are not enough.

Key moments

Tap one to play from there.

  1. 0:00 Why we started the members-only live
  2. 0:57 SGLT2 inhibitors and GLP-1s in non-diabetic CKD
  3. 1:51 The EMPA-KIDNEY trial: 28% risk reduction
  4. 2:25 KDIGO 2024 recommendation for SGLT2 inhibitors
  5. 4:23 The FLOW trial and where GLP-1 kidney data stops
  6. 5:09 How to raise this with your doctor
  7. 5:46 Is creatine safe across CKD stages?
  8. 7:29 Creatine in CKD stage 3 and beyond

What the video says

As stated in the video, not checked by us. Doses and results are the speaker’s, not advice.

Medication
Ozempic and Wegovy
Side effects mentioned
fatigue and muscle loss

Questions this video answers

Can people with CKD but no diabetes take SGLT2 inhibitors?

The speaker says yes. He cites the EMPA-KIDNEY trial, where 54% of participants did not have diabetes, and KDIGO 2024 guidance that applies regardless of diabetes status. He suggests discussing it with a nephrologist if kidney function and urine protein meet the criteria.

Do GLP-1 medications protect the kidneys in people without diabetes?

According to the speaker, the evidence is not there yet. The FLOW trial of semaglutide enrolled only people with type 2 diabetes and CKD, and the FDA approval for kidney protection covers that group. He says he expects positive data in non-diabetic CKD later but does not have it now.

Does foamy urine mean there is protein in the urine?

The speaker says no. He lists causes such as stream force, bowl shape, cleaning products, concentrated urine and holding urine. In a 2012 study he cites, 22.2% of 72 people with foamy urine had overt proteinuria, so he says to rely on the urine albumin creatinine ratio.

How much protein should someone with stage 3 to 5 CKD eat?

The speaker says KDIGO 2024 recommends 0.8 g per kilogram of body weight for adults with stage 3 to 5 CKD who are stable and not on dialysis. He says people with CKD at risk of progression should not exceed 1.3 g per kilogram, and frail or underweight people may need more with a kidney dietitian.

Videos on the same question

The closest videos in the library by what is said in them, not by title.

Read next

Our guides closest to what this video covers, with prices checked weekly.

  • GLP-1 vs GLP-2 vs GLP-3: what the names mean, and which ones you can actually buy

    GLP-1 drugs such as semaglutide act on one receptor. "GLP-2" is used online for tirzepatide (Zepbound, Mounjaro), which acts on two, GIP and GLP-1, and "GLP-3" for retatrutide, which adds the glucagon receptor. Neither nickname is the real name: GLP-2 is a separate gut hormone whose drug, Gattex, treats short bowel syndrome. Retatrutide produced 28.3% mean weight loss at 80 weeks in its phase 3 trial but is not FDA-approved; Lilly plans to file in Q1 2027. Tirzepatide is the strongest option you can buy today.

  • GLP-1s for PCOS: what the guideline allows, what the trials show, and what it costs

    No GLP-1 is FDA approved for PCOS. The 2023 International PCOS Guideline says liraglutide and semaglutide could be considered for higher weight in adults with PCOS, alongside lifestyle changes. The trials agree on weight: a 2026 review of 11 randomized trials showed a modest BMI drop. Effects on periods, hair growth and hormones are less certain, and the guideline keeps fertility use to research settings. Stop semaglutide 2 months before trying to conceive.

  • GLP-1 supplements: what the boosters are, what they did in trials, and what the real drug costs

    No GLP-1 supplement contains a GLP-1 drug. Products sold as GLP-1 boosters, gummies or natural GLP-1 are dietary supplements, usually built on berberine, fiber or probiotics, and FDA does not approve them before they are sold. In trials, berberine averaged about 2 lb (0.88 kg) more weight loss than control across 23 studies; semaglutide, the drug in Wegovy, averaged about 28 lb (12.7 kg) more than placebo at 68 weeks. A real GLP-1 needs a prescription, and the cheapest cash program on our board is $39 a month.

Next steps

Ozempic prices

Insurance

Find more like it

Side effectsDose changeFood, protein and eatingMood and mental healthThe trialsFatigueMuscle loss

Up next

More from this collection

Watched it? See what it costs.

Every GLP-1 program we track, ranked by what actually leaves your account.

Back to GLP-1 TV